Natixis Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$55.9M Sell
2,319,414
-394,139
-15% -$10.3M 0.06% 281
2026
Q1
$76.2M Buy
2,713,553
+508,278
+23% +$13.5M 0.11% 191
2025
Q4
$54.9M Buy
2,205,275
+476,073
+28% +$12M 0.08% 243
2025
Q3
$44.1M Sell
1,729,202
-522,523
-23% -$12.9M 0.06% 278
2025
Q2
$54.6M Sell
2,251,725
-290,771
-11% -$6.78M 0.09% 233
2025
Q1
$64.4M Buy
2,542,496
+318,688
+14% +$8.34M 0.12% 187
2024
Q4
$59M Sell
2,223,808
-174,092
-7% -$4.72M 0.11% 188
2024
Q3
$69.4M Sell
2,397,900
-203,516
-8% -$5.94M 0.14% 160
2024
Q2
$72.8M Buy
2,601,416
+387,856
+18% +$10.7M 0.16% 139
2024
Q1
$61.4M Buy
2,213,560
+980,321
+79% +$27.2M 0.14% 163
2023
Q4
$35.5M Sell
1,233,239
-157,733
-11% -$4.77M 0.09% 229
2023
Q3
$46.1M Sell
1,390,972
-1,061,722
-43% -$37.5M 0.14% 159
2023
Q2
$90M Buy
2,452,694
+1,232,948
+101% +$48M 0.28% 86
2023
Q1
$49.8M Sell
1,219,746
-927,861
-43% -$40.1M 0.17% 143
2022
Q4
$110M Buy
2,147,607
+816,561
+61% +$39.1M 0.42% 54
2022
Q3
$58.2M Sell
1,331,046
-317,452
-19% -$15.4M 0.25% 105
2022
Q2
$86.4M Buy
1,648,498
+50,997
+3% +$2.6M 0.38% 61
2022
Q1
$82.7M Buy
1,597,501
+478,224
+43% +$24.8M 0.32% 71
2021
Q4
$66.1M Buy
1,119,277
+253,047
+29% +$12.5M 0.25% 93
2021
Q3
$37.3M Buy
866,230
+6,647
+0.8% +$294K 0.15% 153
2021
Q2
$33.7M Buy
859,583
+65,556
+8% +$2.55M 0.16% 161
2021
Q1
$28.8M Sell
794,027
-49,574
-6% -$1.76M 0.15% 169
2020
Q4
$31.1M Sell
843,601
-236,315
-22% -$8.67M 0.18% 138
2020
Q3
$37.6M Sell
1,079,916
-171,486
-14% -$6.01M 0.24% 98
2020
Q2
$38.8M Sell
1,251,402
-28,728
-2% -$976K 0.26% 82
2020
Q1
$39.6M Sell
1,280,130
-209,899
-14% -$7.15M 0.32% 68
2019
Q4
$55.4M Buy
1,490,029
+261,612
+21% +$9.32M 0.39% 54
2019
Q3
$41.9M Sell
1,228,417
-178,291
-13% -$6.48M 0.33% 64
2019
Q2
$57.8M Sell
1,406,708
-24,194
-2% -$961K 0.47% 46
2019
Q1
$57.7M Sell
1,430,902
-106,301
-7% -$4.26M 0.5% 41
2018
Q4
$63.7M Buy
1,537,203
+22,808
+2% +$947K 0.63% 33
2018
Q3
$63.3M Sell
1,514,395
-138,466
-8% -$5.33M 0.56% 36
2018
Q2
$56.9M Buy
1,652,861
+71,396
+5% +$2.44M 0.54% 32
2018
Q1
$53.3M Buy
1,581,465
+42,955
+3% +$1.48M 0.53% 32
2017
Q4
$52.9M Buy
1,538,510
+20,714
+1% +$706K 0.54% 34
2017
Q3
$51.4M Buy
1,517,796
+61,398
+4% +$1.97M 0.54% 34
2017
Q2
$46.4M Buy
1,456,398
+52,691
+4% +$1.66M 0.5% 39
2017
Q1
$45.6M Buy
1,403,707
+116,826
+9% +$3.68M 0.5% 41
2016
Q4
$39.7M Buy
1,286,881
+134,941
+12% +$4.12M 0.48% 41
2016
Q3
$37M Buy
1,151,940
+120,164
+12% +$4.02M 0.48% 40
2016
Q2
$34.5M Buy
1,031,776
+41,014
+4% +$1.31M 0.48% 37
2016
Q1
$27.9M Buy
990,762
+121,520
+14% +$3.47M 0.42% 43
2015
Q4
$26.6M Buy
869,242
+22,247
+3% +$700K 0.44% 38
2015
Q3
$25.2M Buy
846,995
+38,986
+5% +$1.25M 0.44% 35
2015
Q2
$25.7M Buy
808,009
+65,997
+9% +$2.15M 0.44% 31
2015
Q1
$24.5M Buy
742,012
+37,406
+5% +$1.19M 0.43% 29
2014
Q4
$20.8M Sell
704,606
-12,986
-2% -$372K 0.39% 35
2014
Q3
$20.1M Sell
717,592
-55,269
-7% -$1.55M 0.4% 33
2014
Q2
$21.8M Sell
772,861
-33,266
-4% -$948K 0.31% 51
2014
Q1
$24.6M Buy
806,127
+29,351
+4% +$875K 0.38% 31
2013
Q4
$22.6M Buy
776,776
+30,721
+4% +$894K 0.37% 34
2013
Q3
$20.3M Buy
746,055
+112,340
+18% +$3.06M 0.37% 34
2013
Q2
$16.8M Buy
+633,715
New +$17.5M 0.34% 45

Other funds holding PFE

Natixis Advisors's PFE Position: Q2 2026 in Review

Natixis Advisors reduced its Pfizer (PFE) stake by 15% in Q2 2026, selling an estimated $10.3M and leaving 2,319,414 shares worth $55.9M. The position accounts for 0.06% of the portfolio, ranked #281.

Natixis Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $110M in Q4 2022. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Natixis Advisors held 2,319,414 shares of Pfizer worth $55.9M as of Q2 2026.
  • Natixis Advisors sold 394,139 Pfizer shares in Q2 2026, an estimated $10.3M.
  • Pfizer made up 0.06% of Natixis Advisors's portfolio in Q2 2026, its #281 holding.
  • Natixis Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Natixis Advisors's Pfizer position peaked at $110M in Q4 2022.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.